IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome
Conditions: Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Anemia, Refractory, With Excess of Blasts Intervention: Drug: IGF/MTX Sponsor: IGF Oncology, LLC Not yet recruiting - verified May 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials